Abstract:Background: Cyclic-dependent kinase (CDK) 4/6 kinases, as the critical drivers of the cell cycle, are involved in the tumor progression of various malignancies. Pharmacologic inhibitors of CDK4/6 have shown significant clinical prospects in treating hormone receptor-positive and human epidermal growth factor receptor-negative (HR + /HER2-) breast cancer (BC) patients. However, acquired resistance to CDK4/6 inhibitors (CDK4/6i), as a common issue, has developed rapidly. It is of great significance that the identification of novel therapeutic targets facilitates overcoming the CDK4/6i resistance. PARP1, an amplified gene for CDK4/6i-resistant patients, was found to be significantly upregulated during the construction of CDK4/6i-resistant strains. Whether PARP1 drives CDK4/6i resistance in breast cancer is worth further study. Method: PARP1 and p-YB-1 protein levels in breast cancer cells and tissues were quantified using Western blot (WB) analysis, immunohistochemical staining (IHC) and immunofluorescence (IF) assays. Bioinformatics analyses of Gene Expression Profiling Interactive Analysis (GEPIA), Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE) datasets were applied to explore the relationship between YB-1/PARP1 protein levels and CDK4/6i IC50. Cell Counting Kit-8 (CCK-8) and crystal violet staining assays were performed to evaluate cell proliferation rates and drug killing effects. Flow cytometry assays were conducted to assess apoptosis rates and the G1/S ratio in the cell cycle. An EdU proliferation assay was used to detect the DNA replication ratio after treatment with PARP1 and YB-1 inhibitors. A ChIP assay was performed to assess the interaction of the transcription factor YB-1 and associated DNA regions. A double fluorescein reporter gene assay was designed to assess the influence of WT/S102A/S102E YB-1 on the promoter region of PARP1. Subcutaneous implantation models were applied for in vivo tumor growth evaluations. Results: Here, we reported that PARP1 was amplified in breast cancer cells and CDK4/6i-resistant patients, and knockdown or inhibition of PARP1 reversed drug resistance in cell experiments and animal models. In addition, upregulation of transcription factor YB-1 also occurred in CDK4/6i-resistant breast cancer, and YB-1 inhibition can regulate PARP1 expression. p-YB-1 and PARP1 were upregulated when treated with CDK4/6i based on the WB and IF results, and elevated PARP1 and p-YB-1 were almost simultaneously observed during the construction of MCF7AR-resistant strains. Inhibition of YB-1 or PAPR1 can cause decreased DNA replication, G1/S cycle arrest, and increased apoptosis. We initially confirmed that YB-1 can bind to the promoter region of PARP1 through a ChIP assay. Furthermore, we found that YB-1 phosphorylated at S102 was crucial for PARP1 transcription according to the double fluorescein reporter gene assay. The combination therapy of YB-1 inhibitors and CDK4/6i exerted a synergistic antitumor effect in vitro and in vivo. The clinical data suggested that HR + /HER2- patients with low expression of p-YB-1/PARP1 may be sensitive to CDK4/6i in breast cancer. Conclusion: These findings indicated that a ''YB-1/PARP1'' loop conferred resistance to CDK4/6 inhibitors. Furthermore, interrupting the loop can enhance tumor killing in the xenograft tumor model, which provides a promising strategy against drug resistance in breast cancer.

YC-1 induced DNA damage and Chk2-mediated E2F1 activation leading to breast cancer cell apoptosis

Anticancer Mechanisms of YC-1 in Human Lung Cancer Cell Line, NCI-H226.

Effect of Proliferation, Cell Cycle, and Bcl-2s of MCF-7 Cells by Resveratrol

Ccdc170 Affects Breast Cancer Apoptosis Through Ire1 Pathway

Proteomic Approach to Studying the Cytotoxicity of YC‐1 on U937 Leukemia Cells and Antileukemia Activity in Orthotopic Model of Leukemia Mice

Effects of YC-1 on Hypoxia-Inducible Factor 1 Alpha in Hypoxic Human Bladder Transitional Carcinoma Cell Line T24 Cells.

Depletion of 4E-Bp1 and Regulation of Autophagy Lead to Yxm110-Induced Anticancer Effects

Effects of YC-1 Targeting Hypoxia-Inducible Factor 1 Alpha in Oesophageal Squamous Carcinoma Cell Line Eca109 Cells.

Pharmacological Targeting of MYC-regulated IRE1/XBP1 Pathway Suppresses MYC-driven Breast Cancer

2-(3-Fluorophenyl)-6-methoxyl-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid (YJC-1) Induces Mitotic Phase Arrest in A549 Cells

Breast Cancer Cells Can Evade Apoptosis-Mediated Selective Killing by A Novel Small Molecule Inhibitor of Bcl-2

The Synthesized 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one (CHM-1) Promoted G2/M Arrest Through Inhibition of CDK1 and Induced Apoptosis Through the Mitochondrial-Dependent Pathway in CT-26 Murine Colorectal Adenocarcinoma Cells

MY11 Exerts Antitumor Effects Through Activation of the NF-κB/PUMA Signaling Pathway in Breast Cancer

MHY2245, a Sirtuin Inhibitor, Induces Cell Cycle Arrest and Apoptosis in HCT116 Human Colorectal Cancer Cells

Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation

Chrysin impairs genomic stability by suppressing DNA double-strand break repair in breast cancer cells

Erk-Modulated Intrinsic Signaling And G(2)/M Phase Arrest Contribute To The Induction Of Apoptotic Death By Allyl Isothiocyanate In Mda-Mb-468 Human Breast Adenocarcinoma Cells

Withanolide C Inhibits Proliferation of Breast Cancer Cells via Oxidative Stress-Mediated Apoptosis and DNA Damage

Chk1 prevents abnormal mitosis of S-phase HeLa cells containing DNA damage

Abstract 5728: YB1 is a novel therapeutic for the treatment of triple negative breast cancer tumors

MHY2251, a New SIRT1 Inhibitor, Induces Apoptosis via JNK/p53 Pathway in HCT116 Human Colorectal Cancer Cells